Navigation Links
Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants

JERUSALEM, Jan. 28, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY) and its portfolio companies ProtAb Ltd. ("ProtAb") and KAHR Medical Ltd. ("KAHR") announced today that they will receive additional funding of NIS 10.7 million (over $2.8 million USD) by the Israeli Ministry of Industry and Commerce, Office of the Chief Scientist (OCS) to support product development and advance clinical trials.

ProtAb received approval for two programs totaling NIS 5.75 million (over $1.5 million USD) at a financing rate of 30% to 50%. The company is developing a novel approach for the treatment of autoimmune diseases based on a biological drug that activates the body's natural anti-inflammatory pathways. This is in contrast to the conventional approach of depressing inflammatory pathways which causes serious side effects and has limited efficacy.

KAHR received approval for two programs totaling NIS 4.95 million (over $1.3 million USD) also at a financing rate of 30% to 50%. The company is developing a platform technology known as SCP (Signal Converter Proteins) enabling the creation of protein based drugs with two active sites, affecting two biological pathways simultaneously with a synergistic effect, providing a distinct advantage over current drugs which have only one active site.

CEO of Hadasit Bio-Holdings, Ophir Shahaf stated, "We are very pleased with the recent grant approvals. Direct funding to our portfolio companies year after year is a vote of confidence and an expression of faith by an external professional agency in our quality of science and management. This additional external financing, which does not dilute the existing shareholders, will allow ProtAb and KAHR to advance towards clinical trials. We are confident that as these companies, as well as the other portfolio companies already in clinical trials advance and report on their successes, we will continue to create value for our share holders."

About Hadasit Bio Holdings
Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. Its portfolio companies develop drugs with blockbuster potential (with markets worth over one billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah. These include ProtAb Ltd. and KAHR Medical, in whom Hadasit Bio-Holdings hold a 70% position and 65% position, respectively.

For more information please visit:

For more information on ProtAb please visit: ProtAb

For more information on KAHR please visit:

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239 /


SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
3. Hadasit Bio-Holdings Interviewed by Wall Street Reporter
4. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
7. Genomic Vision Extends its Patent Portfolio With the Genomic Morse Code
8. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
9. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
10. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
11. LABS, Inc. Among Colorados Top Private Companies
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/25/2015)... Francisco, CA (PRWEB) , ... November 25, 2015 ... ... microbial genomics company uBiome, were featured on AngelList early in their initial angel ... launching an AngelList syndicate for individuals looking to make early stage investments in ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
Breaking Biology News(10 mins):